Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Agenus Inc.NASDAQ: AGEN
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity remains negative
Q1 FY2026 total equity was -$227.98M, compared with -$322.4M a year earlier.
Context
- Total equity amounted to 122.3% of total assets at the end of Q1 FY2026, down 38.8 pp from a year earlier.
- Total equity grew in size in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +29.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (277.86M) USD
- Year-over-year change
- +9.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (277.86M) | +9.3% |
| FY2024 | 2024-12-31 | (306.42M) | -106.5% |
| FY2023 | 2023-12-31 | (148.38M) | -170.3% |
| FY2022 | 2022-12-31 | (54.9M) | -214.6% |
| FY2021 | 2021-12-31 | 47.91M | — |
Total Equity vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's Mar 2026 total equity of -$227.98M is the lowest of the 10 companies compared; the peer median is $87.48M.
- Its year-over-year change of +29.3% is the 2nd highest of 9, against a peer median of -37.9%.
- Total equity amounts to 122.3% of total assets for AGEN, versus a peer median of 68.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $241.48M | -22.4% | -16.6% | 88.7% | |
| Mar 2026 | $182.68M | -38.2% | -20.7% | 72.2% | |
| Mar 2026 | $179.71M | -37.7% | -24.6% | 63.1% | |
| Mar 2026 | $165.17M | -35.8% | -16.7% | 81.5% | |
| Mar 2026 | $87.48M | -43.8% | -28.0% | 65.5% | |
| Mar 2026 | $23.19M | +135.3% | +19.4% | 78.1% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $6.12M | — | — | 32.8% |
| Mar 2026 | $6.07M | -88.2% | -52.3% | 12.2% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$45.84M | -1003.5% | -30.8% | 68.6% |
| Mar 2026 | -$227.98M | +29.3% | — | 122.3% | |
| Peer median (excluding AGEN) | $87.48M | -37.9% | -22.7% | 68.6% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291.93M | 178.67M | 76.11M | 40.44M | 3M |
| Short-term Investments | 14.99M | 14.68M | 0 | 0 | 0 |
| Net Receivables | 1.52M | 2.74M | 25.84M | 407K | 1.83M |
| Inventory | 20.36M | 13.83M | 0 | 0 | 0 |
| Other Current Assets | (17.19M) | (10.64M) | 2.37M | 2.42M | 128.61M |
| Total Current Assets | 331.97M | 213.12M | 112.42M | 45.57M | 133.44M |
| Property, Plant & Equipment (Net) | 91.08M | 164.29M | 163.03M | 147.4M | 24.25M |
| Goodwill | 24.88M | 25.47M | 24.72M | 24.09M | 24.09M |
| Intangible Assets | 8.49M | 6.23M | 4.41M | 3.38M | 3.04M |
| Long-term Investments | 0 | 0 | 3.22M | 4.64M | 42.73M |
| Tax Assets | (2.67M) | (2.67M) | 0 | 0 | 0 |
| Other Non-current Assets | 12.21M | 7.12M | 6.11M | 1.19M | (742K) |
| Total Non-current Assets | 133.98M | 200.43M | 201.5M | 180.7M | 93.36M |
| Total Assets | 465.96M | 413.56M | 313.91M | 226.27M | 226.8M |
| Account Payables | 30.49M | 40.94M | 61.45M | 61.47M | 82.99M |
| Short-term Debt | 728K | 575K | 146K | 2.7M | 155.11M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 12.43M | 12.27M | 18K | 31K | 1.14M |
| Other Current Liabilities | 75.66M | 101.49M | 141.21M | 121.85M | 83.11M |
| Total Current Liabilities | 156.94M | 188.95M | 255.9M | 221.4M | 323.49M |
| Long-term Debt | 12.82M | 12.58M | 12.77M | 30.47M | 169.66M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 11.2M | 1.14M | 1.14M | 1.14M | 1.14M |
| Other Non-current Liabilities | 194.97M | 202.45M | 125.26M | 225.13M | 242K |
| Total Non-current Liabilities | 261.11M | 279.51M | 206.4M | 311.29M | 181.17M |
| Total Liabilities | 418.05M | 468.46M | 462.3M | 532.7M | 504.66M |
| Common Stock | 2.57M | 3.06M | 3.94M | 236K | 353K |
| Retained Earnings | (1.49B) | (1.71B) | (1.96B) | (2.18B) | (2.18B) |
| Accumulated OCI | 1.49M | 915K | (955K) | (1.4M) | (439K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 13.47M | 6.38M | 11.95M | 19.96M | (6.75M) |
| Total Equity | 47.91M | (54.9M) | (148.38M) | (306.42M) | (277.86M) |
| Total Debt | 58.29M | 78.43M | 93.19M | 94.87M | 334.9M |
| Net Debt | (233.64M) | (100.25M) | 17.08M | 54.43M | 331.9M |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.